Important Notes
This annual report summary is derived from the full annual report. To fully understand the company's operational results, financial status, and future development plans, investors should carefully read the full annual report published in designated media by the China Securities Regulatory Commission. All directors attended the board meeting to review this report. Tianzhi International Accounting Firm (Special General Partnership) provided a standard unqualified opinion on the company's financial report for the year. Non-standard audit opinion reminder: □ Applicable ☒ Not applicable.
The company was unprofitable at the time of listing and remains unprofitable. □ Applicable ☒ Not applicable.
The profit distribution plan or capital reserve transfer plan reviewed by the board during the reporting period is ☒ Applicable □ Not applicable.
The profit distribution plan approved by the board is as follows: Based on the total share capital of 180,000,000 shares as of December 31, 2025, excluding 2,360,050 shares held in the repurchase account, a cash dividend of 2.80 yuan (including tax) will be distributed for every 10 shares to all shareholders, with no bonus shares (including tax), and no capital reserve transfer to shareholders for every 10 shares.
The board resolution on the preferred stock profit distribution plan for this reporting period: □ Applicable □ Not applicable.
Company Overview
-
Company Profile
- Stock Abbreviation: Zhenghai Bio
- Stock Code: 300653
- Stock Exchange: Shenzhen Stock Exchange
- Contact Person and Information:
- Secretary of the Board: Zhao Li
- Securities Affairs Representative: Lü Yangqiong
- Office Address: No. 7 Nanjing Street, Yantai Economic and Technological Development Zone
- Fax: 0535-6971993
- Phone: 0535-6971993
- Email: ir@zhbio.com
-
Main Business or Product Overview
The company's main business is the research, production, and sales of biological regenerative materials, establishing a comprehensive business platform covering R&D, clinical, registration, production, quality assurance, and sales. As of now, the company has approved 14 medical device products, of which 10 are Class III medical devices. The products are widely used in oral and maxillofacial surgery, neurosurgery, orthopedics, and trauma surgery. With the continuous improvement of the company's technological platform's industrialization capabilities, the product lineup will continue to expand.
Current Class III Medical Device Products and Applications
| No. | Application Field | Product Name | Applicable Scope |
|---|---|---|---|
| 1 | Oral and Maxillofacial Surgery | Oral Repair Membrane | For the repair of superficial soft tissue defects in the oral cavity and to prevent Frey's syndrome during parotid surgery. |
| 2 | Oral Repair Membrane | For covering and repairing superficial soft tissue defects in the buccal and palatal areas and gingival mucosal tissue. | |
| 3 | Bone Repair Material | For filling and repairing defects (or insufficient bone mass) in the jawbone. | |
| 4 | Calcium Silicate Bio-ceramic Oral Bone Repair Material | Needs to be used with barrier membranes for the repair of alveolar bone defects. | |
| 5 | Light-cured Composite Resin | For direct restoration of anterior and posterior teeth, core build-up, splinting, and indirect restorations (including inlays and onlays). | |
| 6 | Self-etching Adhesive | For bonding light-cured composite resin to enamel and dentin. | |
| 7 | Absorbable Dura (Spinal) Patch | For the repair of dura (spinal) defects. | |
| 8 | Dura (Spinal) Patch | For the repair of dura (spinal) defects. | |
| 9 | Orthopedics | Active Biological Bone | For filling bone defects caused by trauma or surgery that do not affect bone structural stability. |
| 10 | Trauma Surgery | Skin Repair Membrane | For the repair of dermal layer defects. |